Zydus Lifesciences
ZYDUSLIFE · NSE · Pharma · India
Financials at a glance
Source: Yahoo FinanceAnnual
Quarterly · last 5
Revenue (FY2026)
₹27,148 Cr
Net margin
18.6%
Revenue CAGR (3y)
+16.3%
Profit CAGR (3y)
+37.0%
Net profit (FY2026)
₹5,040 Cr
Ask MarketChacha about ZYDUSLIFE
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Financials
Yearly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| FY2026 | ₹27,148 Cr | ₹5,040 Cr | 18.6% |
| FY2025 | ₹23,242 Cr | ₹4,526 Cr | 19.5% |
| FY2024 | ₹19,547 Cr | ₹3,860 Cr | 19.7% |
| FY2023 | ₹17,237 Cr | ₹1,960 Cr | 11.4% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| Q1 FY27 | ₹8,017 Cr | ₹990 Cr | 9.35 | 12.4% |
| Q4 FY26 | ₹7,587 Cr | ₹1,341 Cr* | 12.65 | 17.7% |
| Q3 FY26 | ₹6,865 Cr | ₹1,042 Cr | — | 15.2% |
| Q2 FY26 | ₹6,123 Cr | ₹1,259 Cr | — | 20.6% |
| Q1 FY26 | ₹6,574 Cr | ₹1,467 Cr | — | 22.3% |
* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.
Figures as reported, in ₹ (crore). Source: Yahoo Finance.
Filings & announcements
2026
Shareholder Meeting / Postal Ballot-Outcome of AGM
Regulation 44(3) disclosure of AGM 2026
BSE8/11/2026materialChange in Directors
BSE8/11/2026Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s report
BSE8/11/2026materialShareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of AGM
BSE8/11/2026materialReporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015
BSE8/11/2026Press Release
BSE8/11/2026Press Release
BSE8/11/2026Investor Presentation
BSE8/11/2026Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended On June 30, 2026
Unaudited financial results for the quarter ended on June 30, 2026
BSE8/11/2026Unaudited Financial Results For The Quarter Ended On June 30, 2026
Unaudited financial results for the quarter ended on June 30, 2026
BSE8/11/2026Receipt Of Order From The Office Of The Superintendent Of Stamps, Gandhinagar, Gujarat
Receipt of order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat.
BSE7/29/2026Strikes /Lockouts / Disturbances
Disruption of operations due to heavy rain and water logging
BSE7/25/2026Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR.
BSE7/23/2026
In the news
- Zydus Lifesciences Shares Decline 2.02%, Quarterly Net Profit Drops Amid Revenue GrowthMoneycontrol.com · 8/14/2026
- PNB, Zydus Life, Oberoi Realty: Top stocks to trade — Key levels, target price & stop lossBusiness Today · 8/14/2026
- Zydus Lifesciences - Lenskart Solutions among 7 stocks hitting 52-week highs; surge up to 20% in a monthThe Economic Times · 8/13/2026
- Zydus Lifesciences shares fall 2.31% in early tradeMoneycontrol.com · 8/13/2026
- Stocks to buy in 2026 for long term: Siemens, Zydus Lifesciences among 5 stocks that could give 10-20% returnThe Economic Times · 8/13/2026
- Trade Spotlight: How should you trade Indian Bank, Aarti Industries, Bank of Maharashtra, Hindalco, Zydus...Moneycontrol.com · 8/13/2026
- From Zydus Lifesciences To Greenpanel: Check HDFC Securities' Latest Q1 Ratings, Target Prices, OutlookNDTV Profit · 8/12/2026
- Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked targetThe Economic Times · 8/12/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.